These findings clearly indicate that IL-33 modulates CD4+IFNγ+ cell activation, suggesting that anti-IL-33 treatment in SCC stimulates the differentiation of CD4+IFNγ+ T cells and inhibits the activation of IL-4-producing CD4+ cells, thus favouring an anti-tumour protective immune response. The gene discussed is IL33; the disease is neoplasm.